Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer
Autor: | Pralay Mukhopadyay, Jacek Jassem, Fernando Hurtado de Mendoza, Eva Thomas, Hyun Cheol Chung, Henri Roché, Valorie F. Chan, Rubi K. Li, Luis Fein, Xavier Pivot |
---|---|
Přispěvatelé: | Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), St. Luke's Medical Center, Kaiser Permanente, Yonsei Cancer Center, Centro de Oncologia Rosario, Veterans Memorial Medical Center, Medical University of Gdansk, Hospital Nacional Edgardo Rebagliati Martins, Bristol-Myers Squibb Company, Département d'oncologie médicale, Institut Claudius Regaud, Saas, Philippe, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM) |
Rok vydání: | 2009 |
Předmět: |
Cancer Research
Lung Neoplasms Estrogen receptor MESH: Epidemiologic Methods Deoxycytidine chemistry.chemical_compound 0302 clinical medicine MESH: Liver Neoplasms Antineoplastic Combined Chemotherapy Protocols skin and connective tissue diseases MESH: Treatment Outcome MESH: Antimetabolites Antineoplastic 0303 health sciences Liver Neoplasms Ixabepilone Metastatic breast cancer MESH: Drug Resistance Neoplasm 3. Good health ErbB Receptors MESH: Antineoplastic Combined Chemotherapy Protocols Treatment Outcome Receptors Estrogen Oncology 030220 oncology & carcinogenesis MESH: Receptors Estrogen [SDV.IMM]Life Sciences [q-bio]/Immunology Female Fluorouracil Breast disease Receptors Progesterone medicine.drug MESH: Receptors Progesterone Antimetabolites Antineoplastic medicine.medical_specialty [SDV.IMM] Life Sciences [q-bio]/Immunology Antineoplastic Agents Breast Neoplasms MESH: Receptor Epidermal Growth Factor Biology 03 medical and health sciences Breast cancer Internal medicine Progesterone receptor Biomarkers Tumor medicine Humans MESH: Epothilones Capecitabine 030304 developmental biology MESH: Humans MESH: Deoxycytidine Cancer medicine.disease MESH: Lung Neoplasms Endocrinology chemistry Drug Resistance Neoplasm Epothilones MESH: Tumor Markers Biological Cancer research MESH: Antineoplastic Agents Epidemiologic Methods MESH: Female MESH: Fluorouracil MESH: Breast Neoplasms Tamoxifen |
Zdroj: | European Journal of Cancer European Journal of Cancer, Elsevier, 2009, 45 (17), pp.2940-6. ⟨10.1016/j.ejca.2009.07.015⟩ |
ISSN: | 0959-8049 |
Popis: | International audience; Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease. |
Databáze: | OpenAIRE |
Externí odkaz: |